Search clinical trials for: Alpha-glucosidase inhibitor
Total 68229 results
-
Genzyme, a Sanofi CompanyApproved for marketingGlycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease (Late-Onset)United States
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease | Glycogenesis 2 Acid Maltase DeficiencyUnited States, Canada, Australia
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States
-
Amicus TherapeuticsCompleted
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Grifols Therapeutics LLCCompleted
-
Astellas Pharma IncCompletedType 2 Diabetes MellitusJapan
-
Grifols Therapeutics LLCTerminatedType 1 Diabetes MellitusUnited States
-
LMU KlinikumGenzyme, a Sanofi CompanyCompletedPompe DiseaseGermany, Taiwan, Italy
-
Grifols Therapeutics LLCCompletedEmphysema | Alpha 1-antitrypsin Deficiency (AATD)United States
-
Kenneth MaddenCompletedSyncope | Other Specified HypotensionCanada
-
Grifols Therapeutics LLCTerminatedCOVID-19United States, Brazil, Chile, Colombia, Mexico
-
ShireWithdrawnChronic Obstructive Pulmonary Disease | Alpha1-antitrypsin Deficiency
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIChina
-
Genzyme, a Sanofi CompanyCompletedPompe Disease | Glycogen Storage Disease Type II (GSD II)United States, Russian Federation, United Kingdom, Bulgaria, India, Ukraine
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States, Israel, France, United Kingdom
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, Taiwan, Israel, United Kingdom, France
-
Baxalta now part of ShireBaxter Healthcare, Ltd. (New Zealand), Baxter Healthcare Pty. Ltd. (Australia)CompletedAlpha 1-Antitrypsin DeficiencyAustralia, New Zealand
-
Grifols Therapeutics LLCRecruiting
-
Eli Lilly and CompanyCompletedType 2 Diabetes MellitusJapan
-
TakedaWithdrawnChronic Obstructive Pulmonary Disease (COPD) | Alpha1-Antitrypsin Deficiency
-
Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyTerminatedPompe DiseaseUnited States
-
CSL BehringCompletedEmphysema | Alpha1-proteinase Inhibitor DeficiencyAustralia, Russian Federation, United States, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden, Canada, Czech Republic
-
Taipei Veterans General Hospital, TaiwanNot yet recruitingGlycogen Storage Disease Type II
-
GlaxoSmithKlineCompleted
-
Sun Yat-sen UniversityCompleted
-
Baxalta now part of ShireCompletedAlpha1-antitrypsin DeficiencyUnited States, Canada
-
Baxalta now part of ShireTerminated
-
Kamada, Ltd.CompletedNew Onset Type-1 DiabetesIsrael
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States
-
University of DundeeRecruitingBronchiectasis AdultUnited Kingdom
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Pompe Disease Infantile-OnsetUnited States, France, South Africa
-
Genzyme, a Sanofi CompanyApproved for marketingGlycogen Storage Disease Type II | Glycogenosis 2
-
Baxalta now part of ShireCompletedAlpha 1-Antitrypsin DeficiencyNew Zealand, Australia
-
Michael Campos, MDCSL BehringCompletedAlpha 1 Antitrypsin DeficiencyUnited States
-
Baxalta now part of ShireCompleted
-
CSL BehringRecruitingAcute-graft-versus-host DiseaseUnited States, Korea, Republic of, Spain, Australia, Germany, Italy, Turkey, Japan
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, France, Germany, Israel, Italy, Netherlands, Taiwan
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2Netherlands
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Glycogenosis 2United States
-
Genzyme, a Sanofi CompanyCompletedPompe Disease Late-Onset | Glycogen Storage Disease Type II GSD IIUnited States
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2France
-
University of Massachusetts, WorcesterCompleted
-
Grifols Therapeutics LLCCompletedAlpha 1-Antitrypsin DeficiencyUnited States
-
Genzyme, a Sanofi CompanyTerminatedGlycogenosis 2 | Glycogen Storage Disease Type II (GSD II) | Acid Maltase Deficiency | Pompe Disease (Infantile-Onset)United States, Taiwan, Germany
-
Assiut UniversityNot yet recruitingPre-Eclampsia | Intrauterine Growth Restriction | alpha1 Anti-trypsin
-
Instituto Grifols, S.A.Completed
-
CSL BehringCompletedEmphysema | Alpha 1-proteinase Inhibitor DeficiencyAustralia, Canada, Czech Republic, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden